GALLANT 5 Tesaglitazar Versus Metformin

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2004
This is a 52-week randomized, double-blind, parallel-group, multi-center, active-controlled (metformin) study of tesaglitazar in patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone during the run-in period. The study comprises a 6 week placebo single blind run in period followed by a 52-week a double blind treatment period and a 3-week follow-up period. Tesaglitazar and metformin will be titrated to optimal effect or highest tolerable dose during the first 12 weeks.
Epistemonikos ID: 64bb2e8b5b073888f7c17adbff398c67727740c7
First added on: May 04, 2024